Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials
- PMID: 38420745
- DOI: 10.1177/03635465231224463
Platelet-Rich Plasma Versus Alternative Injections for Osteoarthritis of the Knee: A Systematic Review and Statistical Fragility Index-Based Meta-analysis of Randomized Controlled Trials
Abstract
Background: Based in part on the results of randomized controlled trials (RCTs) that suggest a beneficial effect over alternative treatment options, the use of platelet-rich plasma (PRP) for the management of knee osteoarthritis (OA) is widespread and increasing. However, the extent to which these studies are vulnerable to slight variations in the outcomes of patients remains unknown.
Purpose: To evaluate the statistical fragility of conclusions from RCTs that reported outcomes of patients with knee OA who were treated with PRP versus alternative nonoperative management strategies.
Study design: Systematic review and meta-analysis; Level of evidence, 2.
Methods: All RCTs comparing PRP with alternative nonoperative treatment options for knee OA were identified. The fragility index (FI) and reverse FI were applied to assess the robustness of conclusions regarding the efficacy of PRP for knee OA. Meta-analyses were performed to determine the minimum number of patients from ≥1 trials included in the meta-analysis for which a modification on the event status would change the statistical significance of the pooled treatment effect.
Results: In total, this analysis included outcomes from 1993 patients with a mean ± SD age of 58.0 ± 3.8 years. The mean number of events required to reverse significance of individual RCTs (FI) was 4.57 ± 5.85. Based on random-effects meta-analyses, PRP demonstrated a significantly higher rate of successful outcomes when compared with hyaluronic acid (P = .002; odds ratio [OR], 2.19; 95% CI, 1.33-3.62), as well as higher rates of patient-reported symptom relief (P = .019; OR, 1.55; 95% CI, 1.07-2.24), not requiring a reintervention after the initial injection treatment (P = .002; OR, 2.17; 95% CI, 1.33-3.53), and achieving the minimal clinically important difference (MCID) for pain improvement (P = .007; OR, 6.19; 95% CI, 1.63-23.42) when compared with all alternative nonoperative treatments. Overall, the mean number of events per meta-analysis required to change the statistical significance of the pooled treatment effect was 8.67 ± 4.50.
Conclusion: Conclusions drawn from individual RCTs evaluating PRP for knee OA demonstrated slight robustness. On meta-analysis, PRP demonstrated a significant advantage over hyaluronic acid as well as improved symptom relief, lower rates of reintervention, and more frequent achievement of the MCID for pain improvement when compared with alternative nonoperative treatment options. Statistically significant pooled treatment effects evaluating PRP for knee OA are more robust than approximately half of all comparable meta-analyses in medicine and health care. Future RCTs and meta-analyses should consider reporting FIs and fragility quotients to facilitate interpretation of results in their proper context.
Keywords: fragility index; knee osteoarthritis; platelet-rich plasma; randomized controlled trial.
Conflict of interest statement
One or more of the authors has declared the following potential conflict of interest or source of funding: J.F.O. has received consulting fees from Kaliber.ai. A.P. has received support for education from Smith & Nephew and hospitality payments from Medical Device Business Services. S.M.S. has received consulting fees from Moximed, Smith & Nephew, Miach Orthopaedics, Vericel, and Flexion Therapeutics; research support from Vericel and JRF; speaking fees from Organogenesis and Vericel; and royalties from Organogenesis; and holds stock or stock options in Engage and Stryker. B.U.N. has received consulting fees from Stryker, Wright Medical, and Zimmer Biomet; support for education from Arthrex and Smith & Nephew; consulting fees from Figur8; and a grant from Arthrex; and holds stock or stock options in BICMD. C.L.C. has received consulting fees from Arthrex; research support from Major League Baseball; and publishing royalties from Springer. A.J.K. has received consulting fees from Joint Restoration Foundation, Arthrex, and Responsive Arthroscopy; honoraria from Joint Restoration Foundation; royalties from Arthrex and Responsive Arthroscopy; a grant from DJO; and research support from Aesculap/B.Braun; and serves on the medical board of trustees for the Musculoskeletal Transplant Foundation. AOSSM checks author disclosures against the Open Payments Database (OPD). AOSSM has not conducted an independent investigation on the OPD and disclaims any liability or responsibility relating thereto.
Similar articles
-
Platelet-Rich Plasma Versus Hyaluronic Acid for Knee Osteoarthritis: A Systematic Review and Meta-analysis of Randomized Controlled Trials.Am J Sports Med. 2021 Jan;49(1):249-260. doi: 10.1177/0363546520909397. Epub 2020 Apr 17. Am J Sports Med. 2021. PMID: 32302218
-
Hyaluronic Acid Versus Platelet-Rich Plasma: A Prospective, Double-Blind Randomized Controlled Trial Comparing Clinical Outcomes and Effects on Intra-articular Biology for the Treatment of Knee Osteoarthritis.Am J Sports Med. 2017 Feb;45(2):339-346. doi: 10.1177/0363546516665809. Epub 2016 Oct 21. Am J Sports Med. 2017. PMID: 28146403 Clinical Trial.
-
Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis: A Meta-analysis of Randomized Controlled Trials.Arthroscopy. 2017 Mar;33(3):659-670.e1. doi: 10.1016/j.arthro.2016.09.024. Epub 2016 Dec 22. Arthroscopy. 2017. PMID: 28012636 Review.
-
PRP Injections for the Treatment of Knee Osteoarthritis: The Improvement Is Clinically Significant and Influenced by Platelet Concentration: A Meta-analysis of Randomized Controlled Trials.Am J Sports Med. 2025 Mar;53(3):745-754. doi: 10.1177/03635465241246524. Epub 2025 Jan 3. Am J Sports Med. 2025. PMID: 39751394 Free PMC article.
-
Intra-articular injections of platelet-rich plasma combined with hyaluronic acid versus platelet-rich plasma alone in the treatment of knee osteoarthritis: a systematic review and meta-analysis.Eur J Orthop Surg Traumatol. 2025 Jun 11;35(1):241. doi: 10.1007/s00590-025-04356-8. Eur J Orthop Surg Traumatol. 2025. PMID: 40498171 Review.
Cited by
-
Cartilage Homeostasis under Physioxia.Int J Mol Sci. 2024 Aug 29;25(17):9398. doi: 10.3390/ijms25179398. Int J Mol Sci. 2024. PMID: 39273346 Free PMC article. Review.
-
Optimal frequency of platelet-rich plasma injections for managing osteoarthritis: A longitudinal study.Regen Ther. 2025 Mar 27;29:227-236. doi: 10.1016/j.reth.2025.02.006. eCollection 2025 Jun. Regen Ther. 2025. PMID: 40225051 Free PMC article.
-
Orthobiologics Revisited: A Concise Perspective on Regenerative Orthopedics.Curr Issues Mol Biol. 2025 Apr 2;47(4):247. doi: 10.3390/cimb47040247. Curr Issues Mol Biol. 2025. PMID: 40699646 Free PMC article. Review.
-
Efficacy of arthroscopic cartilage transplantation combined with platelet-rich plasma in the treatment of early knee osteoarthritis: a retrospective cohort study.Langenbecks Arch Surg. 2025 Apr 7;410(1):122. doi: 10.1007/s00423-025-03690-z. Langenbecks Arch Surg. 2025. PMID: 40192784 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials